Core Viewpoint - Intelligent Bio Solutions Inc. has received its eighth European patent, enhancing its intellectual property rights related to fingerprint sweat drug testing technology, which contextualizes chemical analysis with fingerprint deposition volume [1][2][3] Group 1: Patent and Technology Advancements - The newly granted patent protects advancements in analyzing substances in fingerprint sweat by correlating chemical findings with the volume of fingerprint residue [2] - This innovation improves the interpretation of detected substances and strengthens the robustness of the testing process, adding sophistication to the company's testing methodology [2] - The company's European IP portfolio now includes multiple aspects of its screening system, such as lateral flow fingerprint analysis and sample collection cartridges [2] Group 2: Market Position and Product Offering - The grant of the patent reflects the depth of innovation in the company's fingerprint sweat drug testing technology, reinforcing its market position [3] - The Intelligent Fingerprinting Drug Testing Solution offers a faster and more dignified alternative to conventional testing methods, addressing logistical and privacy concerns [3] - The technology screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [4] Group 3: Target Markets and Applications - The company's current customer segments outside the U.S. include construction, manufacturing, transport, mining, drug treatment organizations, and coroners [4] - The technology is designed to be hygienic and cost-effective, making it a valuable tool for employers in safety-critical industries [4]

Core Insights - Intelligent Bio Solutions Inc. (INBS) has partnered with Bouygues UK to deploy its fingerprint drug testing technology across 13 project sites, marking a shift from third-party testing to an in-house solution that emphasizes hygiene, efficiency, and cost savings [1][3][4] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat for drug use [5] - The company aims to revolutionize portable testing in safety-critical industries, with applications in construction, manufacturing, transport, and more [5] Partnership Details - Bouygues UK, a subsidiary of Bouygues Construction, operates in over 50 countries and reported a turnover of €10.3 billion in 2024 [2] - The partnership is characterized as a collaborative relationship rather than a traditional supplier-customer dynamic, with both parties emphasizing mutual understanding and alignment with workplace safety culture [3][4] Operational Advantages - The transition to in-house drug testing is expected to provide Bouygues UK with greater control over the testing process, enhancing workplace hygiene and employee experience while also confirming substantial cost savings through ROI analysis [4] - The fingerprint drug testing technology has been validated for its operational advantages in high-stakes construction environments, reinforcing its economic viability for large-scale applications [4]

Core Insights - Intelligent Bio Solutions Inc. reported a revenue of over $2 million for the first half of fiscal 2026, reflecting a 36% year-over-year increase [1][8] - Reader sales more than doubled, increasing by 104% year-over-year in the second quarter, indicating strong market demand for the company's non-invasive drug testing technology [3][7] - Gross profit margins improved to 49%, up 10% from the previous year, showcasing enhanced operational efficiency [1][8] Financial Performance - For the three months ended December 31, 2025, total revenue reached $896,774, a 48% increase year-over-year, driven by significant growth in reader and cartridge sales [5][7] - Reader sales for the second quarter amounted to $246,519, up 104% from $120,787 in the same period last year, while cartridge sales grew by 33% to $516,754 [5][7] - For the six months ended December 31, 2025, total revenue was $2,008,571, with reader sales increasing by 50% to $533,432 and cartridge sales growing by 38% to $1.2 million [8][17] Operational Highlights - The company added 49 new customer accounts in the first half of fiscal 2026, indicating sustained customer adoption across international markets [8] - A new manufacturing partnership was announced, expected to enhance gross profit margins and drive cost efficiencies [6][12] - The company is progressing towards FDA 510(k) submission, aiming for entry into the U.S. market, which is projected to be a multi-billion-dollar opportunity [5][12] Strategic Initiatives - The company formed a strategic alliance with Vlepis Pty Ltd to enter the consumer health monitoring market, broadening revenue opportunities beyond commercial screening [12] - A major contract was secured with a leading industrial service provider, further expanding the company's presence in safety-critical sectors [12] - The company is focused on maintaining financial discipline while investing in commercial expansion linked to operational results [3][12]

Core Insights - Intelligent Bio Solutions Inc. anticipates record revenue growth for fiscal Q2 2026, driven by an expanding customer base and strong performance across all product categories [1][2] - Reader sales are expected to more than double year-over-year, with a growth rate exceeding 100% in fiscal Q2 [1][2] - The company emphasizes a razor-razorblade business model, where each reader placement fosters long-term relationships that generate recurring cartridge revenue [2] Revenue Expectations - Total revenue for fiscal Q2 2026 is projected to be approximately $2.01 million, reflecting a 36% year-over-year increase [5] - Cartridge sales are expected to rise by approximately 38% year-over-year, while reader sales are anticipated to increase by about 50% year-over-year [5] - Other sales, including accessories and training, are expected to grow by approximately 10% year-over-year [5] Business Model and Strategy - The anticipated 33% growth in cartridge sales illustrates the effectiveness of the company's business model, highlighting new customer adoption and ongoing demand for consumables [2] - The company is confident in its commercial strategy and aims to capture greater market share as its installed reader base expands [2] - The Intelligent Fingerprinting Drug Screening System is positioned to revolutionize portable testing through rapid, non-invasive methods, targeting various industries such as construction and logistics [3]

Core Insights - Intelligent Bio Solutions Inc. has initiated a clinical study program to support its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System, aimed at detecting the opiate codeine [1][5] - The U.S. drug screening market presents a significant commercial opportunity, generating several billion dollars annually across various sectors [4] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, with a focus on fingerprint-based drug screening technology [6] - The Intelligent Fingerprinting Drug Screening System is designed to be hygienic, cost-effective, and capable of providing results in under ten minutes, making it suitable for safety-critical industries [6] Clinical Study Details - The first clinical study will involve 40 adults and will assess codeine detection cut-off levels using the Intelligent Fingerprinting Drug Screening Cartridge and DSR-Plus fluorescence reader [3] - The study will compare results with an FDA-cleared device and will utilize liquid chromatography-tandem mass spectrometry (LC-MS/MS) for corroboration [3] Market Potential - The U.S. drug screening market is the largest globally, with applications in workplace testing, criminal justice, pain management, and substance abuse treatment [4] - The company's technology offers advantages over traditional testing methods, including improved hygiene, ease of use, rapid results, and reduced collection costs [4] Strategic Partnerships - The company has partnered with Cliantha Research, a clinical research organization, to leverage its expertise in regulatory and clinical trials [2] - Subject recruiting and screening for the clinical study have already begun, with the first testing cohort starting on January 28, 2026 [5]

Core Viewpoint - Intelligent Bio Solutions Inc. has successfully closed a private placement with institutional investors, raising approximately $10 million to support its operations and product development [1][2]. Group 1: Private Placement Details - The private placement involved the issuance of 2,298,850 shares of common stock and associated Series K-1 and K-2 warrants, priced at $4.35 per share [1]. - The Series K-1 and K-2 warrants have an exercise price of $4.10 per share and are exercisable immediately upon issuance, with a term of five years [1]. - The expected gross proceeds from this placement are approximately $10 million, before deducting fees and expenses [1]. Group 2: Use of Proceeds - The company intends to utilize the proceeds for working capital and general corporate purposes, including funding its 510(k) submission with the FDA for its Intelligent Fingerprinting Drug Screening System [2]. - The funds will also support the company's efforts to expand into international markets [2]. Group 3: Company Overview - Intelligent Bio Solutions Inc. specializes in non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [5]. - The system is designed to be hygienic and cost-effective, screening for drugs commonly found in workplace settings, including opiates, cocaine, methamphetamine, and cannabis [5]. - The company targets various customer segments outside the U.S., including construction, manufacturing, transport, and drug treatment organizations [5].

Core Viewpoint - Intelligent Bio Solutions Inc. has entered into a securities purchase agreement to raise approximately $10 million through a private placement of common stock and warrants, aimed at enhancing its working capital and general corporate purposes [1][2]. Group 1: Securities Offering - The company will issue 2,298,850 shares of common stock and associated Series K-1 and K-2 warrants, priced at $4.35 per share, with expected gross proceeds of around $10 million before expenses [1]. - The Series K-1 and K-2 warrants will have an exercise price of $4.10 per share and will be exercisable immediately upon issuance, with a term of five years [1]. - The closing of the private placement is anticipated on or about January 2, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Intelligent Bio Solutions Inc. specializes in medical technology, focusing on intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [5]. - The company's technology allows for quick sample collection and results in under ten minutes, targeting industries such as construction, manufacturing, and transport [5].

Core Insights - Intelligent Bio Solutions Inc. (INBS) has formed a strategic manufacturing partnership with Syrma Johari MedTech to enhance its production capabilities and support its entry into the U.S. market in 2026 [1][3]. Group 1: Partnership Benefits - The partnership is expected to yield annual production cost savings exceeding 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin compared to previous manufacturing arrangements [2]. - Syrma Johari's manufacturing capacity is about four times that of INBS, enabling the company to efficiently meet anticipated demand as it scales its commercial operations [2]. Group 2: Supply Chain Resilience - This collaboration strengthens INBS' global manufacturing strategy by reducing reliance on a single supplier and enhancing supply chain resilience [3]. - The partnership broadens manufacturing capacity, ensures continuity, and creates flexibility in preparation for future demand across multiple regions [3]. Group 3: Syrma Johari's Capabilities - Syrma Johari has over 45 years of experience in medical device engineering and manufacturing, operating 14 manufacturing locations and four design and innovation centers globally [4]. - The company is certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring high compliance and quality in medical device manufacturing [4]. Group 4: Production Efficiency - Syrma Johari's vertical integration and export-oriented model facilitate high-quality production while optimizing sourcing, tooling, testing, and logistics [5]. - The company is set to open a new medical-grade plastics manufacturing facility in India in January 2026, further enhancing its capabilities to meet global demand [5]. Group 5: Regulatory Support - Syrma Johari's extensive regulatory and quality-assurance capabilities align with INBS' global expansion plans, providing end-to-end quality systems and regulatory documentation support [6]. - This expertise will assist INBS in advancing its regulatory pathways and preparing for increased commercial activity worldwide [6]. Group 6: Strategic Importance - The partnership is viewed as a significant milestone for INBS, enhancing its supply chain and supporting future growth [7]. - Both companies express a strong alignment in innovation, quality, and long-term vision, indicating a commitment to scaling disruptive drug-screening technology [7][8].

Core Viewpoint - Intelligent Bio Solutions Inc. will implement a 1-for-10 reverse stock split effective December 15, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on providing intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [4]. - The company aims to revolutionize portable testing via fingerprint sweat analysis, targeting industries such as construction, manufacturing, transport, and drug treatment organizations [4]. Reverse Stock Split Details - The reverse stock split will combine every 10 shares of common stock into one share, with no fractional shares issued; instead, stockholders will receive cash for any fractional shares [3]. - After the split, the par value of the common stock will remain at $0.01 per share, and the total number of authorized shares will stay at 100 million [3]. - Following the reverse split, approximately 959,533 shares of common stock will be issued and outstanding [3].

Core Insights - Intelligent Bio Solutions Inc. will participate in the 21st Annual Emerging Growth Equity Conference hosted by Noble Capital Markets on December 2-3, 2025 [1] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [4] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [4] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [4] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [4] Conference Details - The conference will take place at Florida Atlantic University, Boca Raton, FL, with Intelligent Bio Solutions scheduled to present on December 3, 2025, at 11:00 a.m. Eastern Time [2] - A webcast recording of the presentation will be available on the company's investor relations website and Noble's website for 90 days post-event [2]